Advancements in B-cell Maturation Antigen (BCMA) Targeted Therapies for Multiple Myeloma Treatment

Multiple myeloma is a hematological malignancy characterized by the uncontrolled proliferation of plasma cells in the bone marrow. B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily, has emerged as a promising target for the treatment of multiple myeloma.

BCMA is selectively expressed on the surface of mature B-cells and plasma cells, making it an attractive target for targeted therapies.

Get more insights on B-cell Maturation Antigen (BCMA) Targeted Therapies - https://www.coherentmarket...

#BCMATargetedTherapies
#BCellMaturationAntigen
#BCMA
#CoherentMarketInsights